Medically reviewed by Susan Bard, MD Atopic dermatitis is the most common type of eczema, and it's primarily diagnosed by a ...

Netherlands: A recent real-world, long-term study from the BioDay Registry has highlighted a significant incidence of ...

Atopic dermatitis is an allergy affecting approximately 10% of the Japanese population, with symptoms closely related to ...

Discover expert-relief solutions for managing atopic dermatitis, from breakthrough treatments to daily habits that prevent ...

Some patients with atopic dermatitis who qualify for advanced systemic therapies do not receive them or may lack improvement with these therapies.

Skin microbes do more than coexist—they shape immune responses, repair tissue, and influence gene expression across your ...

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.

Patent protection for ZORYVE cream 0.3% extends until at least 2037. ZORYVE cream 0.3% is indicated for the topical treatment of plaque psoriasis, including intertriginous areas, in adult and ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Atopic dermatitis is an allergy affecting approximately 10% of the Japanese population, with symptoms closely related to ...